<DOC>
	<DOCNO>NCT01478568</DOCNO>
	<brief_summary>The study aim evaluate blood level desipramine change whilst dose time daily mirabegron .</brief_summary>
	<brief_title>To Evaluate Effect Mirabegron ( YM178 ) Blood Levels Desipramine When They Are Taken Together</brief_title>
	<detailed_description>This open-label , one-sequence crossover design study evaluate drug-drug interaction mirabegron desipramine . The effect mirabegron plasma concentration desipramine evaluate 13 day repeat administration . The recovery CYP2D6 activity also explore compare pharmacokinetic profile desipramine 2 week wash-out period .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Desipramine</mesh_term>
	<criteria>Body Mass Index 18.5 30.0 kg/m2 inclusive Subject genotyped phenotyped extensive metabolizer CYP2D6 Known suspect hypersensitivity YM178 component formulation use Known suspect hypersensitivity desipramine component formulation use Pregnant breast feeding within 6 month screen assessment Any clinical history major depressive disorder , cardiovascular disease , urinary retention , glaucoma , thyroid disease and/or seizure disorder Any liver function test ( i.e . Alanine Aminotransferase ( ALT ) , Asparate Aminotransferase ( AST ) Alkaline phosphatase ) upper limit normal repeat measurement Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug ( exclude nonactive hay fever ) Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test Abnormal pulse rate and/or blood pressure measurement prestudy visit follow : pulse rate &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 140 mmHg ; mean diastolic blood pressure &gt; 90 mmHg ( blood pressure measurement take triplicate subject rest supine position 5 min ; pulse rate measure automatically ) A marked baseline prolongation QT/QTc interval repeat measurement &gt; 450 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Phase 1</keyword>
</DOC>